Srinagar, May 30: Directorate of Health Services, Kashmir, has ordered the immediate discontinuation of a specific batch of Injection Bupivacaine Hydrochloride following reports of adverse post-operative reactions.
The directorate has directed all Chief Medical Officers and Medical Superintendents across the Kashmir division to stop using the drug with immediate effect.
The circular pertains to the batch bearing the number AA4012B, manufactured in March 2024 and set to expire in February 2026. Though the nature of the adverse reactions has not been detailed in the communication, the directive has been issued as a precautionary measure to safeguard patient health.
Injection Bupivacaine Hydrochloride is commonly used as a local anesthetic during surgeries and other medical procedures. The order aims to prevent any further complications that may arise from its continued use.
Further investigations and quality checks are expected to follow.
|